1. Home
  2. WVE vs GDRX Comparison

WVE vs GDRX Comparison

Compare WVE & GDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • GDRX
  • Stock Information
  • Founded
  • WVE 2012
  • GDRX 2011
  • Country
  • WVE Singapore
  • GDRX United States
  • Employees
  • WVE N/A
  • GDRX N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • GDRX Retail: Computer Software & Peripheral Equipment
  • Sector
  • WVE Health Care
  • GDRX Technology
  • Exchange
  • WVE Nasdaq
  • GDRX Nasdaq
  • Market Cap
  • WVE 915.6M
  • GDRX 913.1M
  • IPO Year
  • WVE 2015
  • GDRX 2020
  • Fundamental
  • Price
  • WVE $7.35
  • GDRX $2.69
  • Analyst Decision
  • WVE Strong Buy
  • GDRX Buy
  • Analyst Count
  • WVE 14
  • GDRX 10
  • Target Price
  • WVE $20.50
  • GDRX $5.48
  • AVG Volume (30 Days)
  • WVE 3.6M
  • GDRX 2.9M
  • Earning Date
  • WVE 11-10-2025
  • GDRX 11-04-2025
  • Dividend Yield
  • WVE N/A
  • GDRX N/A
  • EPS Growth
  • WVE N/A
  • GDRX N/A
  • EPS
  • WVE N/A
  • GDRX 0.09
  • Revenue
  • WVE $109,230,000.00
  • GDRX $800,651,000.00
  • Revenue This Year
  • WVE N/A
  • GDRX $2.72
  • Revenue Next Year
  • WVE $6.24
  • GDRX $5.30
  • P/E Ratio
  • WVE N/A
  • GDRX $31.33
  • Revenue Growth
  • WVE 103.75
  • GDRX 1.30
  • 52 Week Low
  • WVE $5.28
  • GDRX $2.61
  • 52 Week High
  • WVE $16.38
  • GDRX $5.81
  • Technical
  • Relative Strength Index (RSI)
  • WVE 49.41
  • GDRX 27.13
  • Support Level
  • WVE $6.60
  • GDRX $2.96
  • Resistance Level
  • WVE $7.27
  • GDRX $3.05
  • Average True Range (ATR)
  • WVE 0.53
  • GDRX 0.15
  • MACD
  • WVE -0.04
  • GDRX -0.01
  • Stochastic Oscillator
  • WVE 51.78
  • GDRX 10.80

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About GDRX GoodRx Holdings Inc.

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Share on Social Networks: